Compare Msci Inc (MSCI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Viatris Inc — how do they compare? Msci Inc trades at $562.98 (market cap $45.51B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Msci Inc is far larger — about 2.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| MSCI | VTRS | |
|---|---|---|
Market Cap | $45.51B | $19.79B |
Sector | Financials | Health |
52-Week High | $643.83 | $17.39 |
52-Week Low | $511.84 | $8.74 |
Enterprise Value | $51.67B | $32.00B |
Dividend Yield | 1.31% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
